200 ventilators ‘gave’ by Trump to cost India $2.6 million: Report Kumar Jeetendra | May 18, 2020 The assessed cost of every versatile ventilator “gave” by the United States to India is about Rs 10 lakh. The US will carrier 200 such portable ventilators, According to a report by the Hindustan Times. An administration official told the paper that the transfer will show up by May-end or most recent by early June. …
ICMR issues overhauled Covid-19 testing methodology Kumar Jeetendra | May 18, 2020 New Delhi, May 18 (IANS) The Indian Council of Medical Research (ICMR), here on Monday, discharged a modified Covid-19 testing system, which included testing of all suggestive flu like ailment (ILI) among returnees and transients inside 7 days of disease. As per new system, no crisis methodology (counting conveyances) ought to be deferred for the …
HIV medication may supplant HCQ in ICMR’s amended COVID-19 treatment convention: Report Kumar Jeetendra | May 19, 2020 The Indian Council of Medical Research (ICMR) is surveying its COVID-19 treatment rules. The wellbeing authority may drop hydroxychloroquine, prevalently called HCQ, from the convention because of expanding question over its viability, The Economic Times has revealed. The report recommends that ICMR is probably going to incorporate HIV blend medications and FDA-endorsed Ivermectin alongside enhancements …
Bharat Biotech, Thomas Jefferson University ties up to create antibody for Covid-19 Kumar Jeetendra | May 21, 2020 Antibody producer Bharat Biotech and Thomas Jefferson University of Philadelphia have marked a restrictive deal to build up another immunization contender for Covid-19. The epic immunization was created utilizing a current deactivated rabies antibody as a vehicle for coronavirus proteins. This immunization is known to create a solid invulnerable reaction and is affirmed for the …
Antibody improvement resembles rollercoaster, says Adar Poonawalla CEO Serum Institute of India Kumar Jeetendra | May 22, 2020 Adar Poonawalla, CEO, Serum Institute of India (SII), said on Thursday that building up an antibody resembles a rollercoaster ride with high points and low points. “Building up an antibody resembles riding a rollercoaster; there are a lot of high points and low points. Some of the time we come up short, here and there …
Novavax begins Phase 1 clinical preliminary of coronavirus immunization competitor Kumar Jeetendra | May 26, 2020 Novavax Inc said on Monday it has begun the Phase 1 clinical preliminary of a novel coronavirus antibody applicant and has selected the preliminary’s first members, with primer outcomes scheduled for July. The Maryland-based late-stage biotechnology organization in April said it distinguished the up-and-comer, NVX-CoV2373, with which it intended to utilize its Matrix-M adjuvant to …
China says two new coronavirus cases, asymptomatic case on German sanction Kumar Jeetendra | May 31, 2020 China declared on Sunday two new affirmed instances of coronavirus and four new asymptomatic cases, including one individual without side effects of COVID-19 on a contracted departure from Germany. The two affirmed cases in Shandong territory on Saturday contrasted and four cases the day preceding, information from the nation’s wellbeing authority appeared. The National Health …
Group invulnerability as COVID-19 system unsafe, nations must make opportune mediations: CSIR Kumar Jeetendra | June 1, 2020 Putting money on creating group insusceptibility to battle coronavirus is “too enormous a hazard” for any country and just opportune intercessions can alleviate the spread of COVID-19, Director General of the Council of Scientific and Industrial Research (CSIR) Shekhar Mande said. Group insusceptibility is accomplished when most of populace gets resistant to an irresistible malady, …
WHO proceeds with hydroxychloroquine preliminary after UK test stops Kumar Jeetendra | June 6, 2020 The World Health Organization (WHO) is proceeding with its clinical preliminary of hydroxychloroquine, after British researchers ended an enormous preliminary that had been investigating utilization of the medication to treat patients with COVID-19 when beginning outcomes indicated no proof of advantage. “There are two unmistakable preliminaries with their own conventions, their own oversight advisory groups. …
Moderna competes with US researchers over COVID-19 antibody preliminaries Kumar Jeetendra | July 7, 2020 As america hastens the search to get a coronavirus vaccine, tensions have escalated between government scientists and Moderna Inc, among the leading programmers, Reuters has heard. The national government is supporting Moderna’s vaccine job by almost half a billion dollars and it has chosen it as one of the earliest to get into large-scale human …
